Royalty Pharma PLC RPRX
We take great care to ensure that the data presented and summarized in this overview for Royalty Pharma plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RPRX
View all-
Morgan Stanley New York, NY44.2MShares$1.19 Billion0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.7MShares$1.01 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY21.2MShares$570 Million0.02% of portfolio
-
Baillie Gifford & CO16.7MShares$448 Million0.4% of portfolio
-
Viking Global Investors LP11.5MShares$309 Million1.33% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA10.8MShares$291 Million0.64% of portfolio
-
State Street Corp Boston, MA9.1MShares$245 Million0.01% of portfolio
-
Swedbank Ab Stockholm, V78.28MShares$223 Million0.42% of portfolio
-
Jpmorgan Chase & CO New York, NY8MShares$215 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA6.55MShares$176 Million0.02% of portfolio
Latest Institutional Activity in RPRX
Top Purchases
Top Sells
About RPRX
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Insider Transactions at RPRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2024
|
Gregory Norden Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+11.19%
|
-
|
|
Jun 07
2024
|
David C Hodgson Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+26.55%
|
-
|
|
Jun 07
2024
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+16.74%
|
-
|
|
Jun 07
2024
|
Errol B Desouza Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+11.19%
|
-
|
|
Jun 07
2024
|
Catherine M. Engelbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+17.6%
|
-
|
|
Jun 07
2024
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+15.35%
|
-
|
|
Jun 07
2024
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,293
+14.01%
|
-
|
|
May 13
2024
|
Christopher Hite EVP & Vice Chairman |
BUY
Conversion of derivative security
|
Indirect |
300,000
+44.78%
|
-
|
|
Mar 28
2024
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,240
+2.87%
|
$37,200
$30.23 P/Share
|
|
Mar 28
2024
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,240
+2.53%
|
$37,200
$30.23 P/Share
|
|
Feb 20
2024
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Direct |
300,000
+48.38%
|
-
|
|
Jan 04
2024
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
35,702
-63.98%
|
$963,954
$27.55 P/Share
|
|
Jan 03
2024
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
199,098
-78.11%
|
$5,375,646
$27.79 P/Share
|
|
Jan 02
2024
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Direct |
235,200
-47.99%
|
$6,585,600
$28.52 P/Share
|
|
Dec 29
2023
|
Avara Management LTD |
SELL
Open market or private sale
|
Indirect |
65,803
-2.59%
|
$1,842,484
$28.04 P/Share
|
|
Dec 29
2023
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,353
+2.83%
|
$36,531
$27.71 P/Share
|
|
Dec 29
2023
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,353
+3.22%
|
$36,531
$27.71 P/Share
|
|
Dec 28
2023
|
Avara Management LTD |
SELL
Open market or private sale
|
Indirect |
209,863
-7.62%
|
$5,876,164
$28.2 P/Share
|
|
Dec 27
2023
|
Avara Management LTD |
SELL
Open market or private sale
|
Indirect |
41,729
-1.49%
|
$1,168,412
$28.01 P/Share
|
|
Dec 15
2023
|
Avara Management LTD |
SELL
Open market or private sale
|
Indirect |
10,229
-0.36%
|
$286,412
$28.01 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 75.4K shares |
|---|---|
| Conversion of derivative security | 1.23M shares |
| Open market or private purchase | 130K shares |
| Open market or private sale | 1.62M shares |
|---|---|
| Other acquisition or disposition | 383K shares |